Actively Recruiting
Phase 2 Study of Sacituzumab Govitecan and Nivolumab After Surgery in Adults With Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence
Led by University of California, Irvine · Updated on 2026-04-30
23
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a phase 2, single-arm clinical trial of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients who have muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract. These patients are considered high risk for cancer recurrence after curative-intent surgery based on surgical pathology. The study aims to understand the effects of this combination therapy in reducing recurrence risk in this population. Participants will receive the combination treatment of Sacituzumab Govitecan and Nivolumab administered intravenously for 4 cycles. This is followed by an additional 11 cycles of single-agent Nivolumab. The treatment is designed to be given after surgery and aims to assess outcomes over an extended period. During the study, participants will undergo various assessments including imaging to confirm disease-free status before starting treatment and ongoing monitoring for cancer recurrence or progression. Researchers will track outcomes such as disease-free survival, time to distant metastases or death, and changes in circulating tumor DNA over up to 5 years. Safety and recovery from prior treatments will also be monitored throughout the trial period.
CONDITIONS
Brief Title
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
U
University of California Irvine Medical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here